Abzyme’s modular antibody platform for creating bispecific antibodies is extremely versatile.

Single domain antibodies can easily be fused to another VHH fragment, a Fab fragment, scFv, or an intact, standard IgG to create novel bispecific therapeutics. Our rapid fusion methods transform existing antibodies into bispecifics without compromising the original binding affinity. Abzyme bispecifics, Abz2, retain the benefits of a traditional antibody, with favorable pharmacokinetics, ability to mobilize immune effector functions, and low immunogenicity.